Plain-English translation of NCT04716686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called as a maintenance or recurrent treatment for women with advanced endometrial serous cancer. works by blocking a protein that cancer cells use to repair their DNA, which makes it harder for cancer to grow. The medication has already been approved by the FDA for treating similar types of ovarian cancer.
Endometrial serous cancer is a rare and aggressive type of uterine cancer that behaves similarly to high-grade ovarian cancer. Research shows that this medication could be effective for this type of cancer, but it hasn't been thoroughly tested in women specifically diagnosed with endometrial serous cancer yet.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily at home for cycles of 28 days. Your doctor will determine your starting dose based on your weight and blood cell counts. You will visit the clinic every 8 weeks for check-ups and blood tests to monitor how well the treatment is working and watch for side effects. The study continues until your cancer progresses, you experience unmanageable side effects, or you decide to stop.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China